Moreover, the earlier detection of NPM1-mutated AML has become more important as venetoclax-based therapies, new menin, and exportin 1 (XPO1) inhibitors can disrupt genetically rearranged molecular perturbations within leukemic cells, leading to more personalized and effective antileukemia treatment [14,15,16,17,18]. The gene discussed is XPO1; the disease is acute myeloid leukemia.